GlaxoSmithKline Pharma net profit rises 8 percent to Rs 116 crore in Q1

Revenue from operations rose to Rs 745 crore as against Rs 718 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a regulatory filing.

Published On 2022-07-26 04:00 GMT   |   Update On 2022-07-26 06:45 GMT
Advertisement

New Delhi: GlaxoSmithKline Pharmaceuticals on Monday said its consolidated net profit increased by 8 per cent to Rs 116 crore in the first quarter ended on June 30, 2022.

The drug firm had reported a net profit of Rs 107 crore in the April-June quarter of the previous year.

Revenue from operations rose to Rs 745 crore as against Rs 718 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a regulatory filing.

Advertisement

Read also: GSK-Sanofi variant-specific COVID vaccine found effective against Omicron

"Our results reflect good momentum across general medicines and vaccines during the quarter. We have delivered strong underlying growth with market share gains across focus brands," GlaxoSmithKline Pharmaceuticals MD Sridhar Venkatesh noted..

The drug firm is a subsidiary of GSK plc, a global biopharma company.

Read also: GSK spins off consumer health business Haleon

GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company headquartered in Mumbai, Maharashtra, India. The company was founded in 1924. Its product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease and respiratory diseases.



Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News